Company Description
Medlab Clinical is an Australian biotechnology company that formulates innovative solutions and innovative consumer health care products to provide integrative patient care.
Our aim is to disrupt the multi-billion-dollar market of delivery platform technologies for pharmaceutical products that are designed to treat pain and mental health.
We were incorporated in Australia in April 2014, and in 2015 listed on the ASX under the symbol “MDC.” Our corporate headquarters are located in Australia, and we maintain offices in the United States and Europe.
Though we do have sales from our products, we are primarily in a research and product development phase and do not generate significant revenue.
NanoCelle®, our core product offering, is a pharmaceutical-delivery platform which is designed to safely administer pharmaceutical products using nanoparticles, or small particles ranging between 1 to 100 nanometres in size and undetectable by the human eye.
NanoCelle® is an alternative, and, we believe, more effective method of consuming medical products compared to the traditional methods.
We develop targeted fixed-dose combinations of the NanoCelle® delivery platform and various active pharmaceutical ingredients, applying proprietary insights to create long-term products that we believe will better meet the medical needs of our patients compared to what is currently available and that we believe will create value for our shareholders.
Our focus is on clinical indications that we believe represent unmet or inadequately addressed medical needs and represent compelling commercial opportunities.
To date, NanoCelle® has administered over 350,000 doses of pharmaceutical products to patients through its delivery platform through compassionate use programs in the U.K.
and Australia or clinical trials and/or sales of medicines approved by such governments or applicable pharmaceutical regulatory agents.
| Country | Australia |
| Founded | 2014 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 42 |
| CEO | Dr. Sean Hall |
Contact Details
Address: Units 5 and 6, 11-13 Lord Street Botany, New South Wales 2019 Australia | |
| Phone | + 61 2 8188 0311 |
| Website | medlab.co |
Stock Details
| Ticker Symbol | MDLB |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $4.45 |
| CIK Code | 0001940322 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mr. Michael Hall | Chairman |
| Dr. Sean Hall | Chief Executive Officer and Managing Director |
| Mr. Drew Townsend | Director |
| Ms. Cheryl Maley | Director |
| Mr. Mohit Gupta | Director |
| Mr. Kerem Kaya | Chief Financial Officer and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 6, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 22, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 4, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Oct 13, 2022 | F-1 | Registration statement for certain foreign private issuers |
| Sep 2, 2022 | DRS | [Cover] Draft Registration Statement |